Ultragenyx Pharmaceutical | RARE - Current Liabilities


Ultragenyx Pharmaceutical reported $325M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Agios Pharmaceuticals USD 58.84M 23.36M Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Esperion Therapeutics USD 300.36M 451K Mar/2026
Immunic USD 38.36M 7.74M Mar/2026
Insmed USD 361.01M 107.87M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Kyowa Hakko Kirin JPY 144.64B 36.43B Mar/2026
MacroGenics USD 95.94M 52.82M Mar/2026
Moderna USD 2.4B 408M Mar/2026
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
PTC Therapeutics USD 923.6M 44.82M Mar/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026
Xoma USD 28.3M 6.81M Sep/2025